PMID: 15232334Jul 3, 2004Paper

A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence

Journal of Clinical Psychopharmacology
Raymond F AntonSakari Karhuvaara

Abstract

The opiate antagonist nalmefene has been shown in 2 single-site studies to reduce alcohol consumption and relapse drinking in alcohol-dependent individuals. This safety and preliminary multisite efficacy study evaluated 3 doses of nalmefene (5, 20, or 40 mg) in a double-blind comparison to placebo over a 12-week treatment period in 270 recently abstinent outpatient alcohol-dependent individuals. Participants concomitantly received 4 sessions of a motivational enhancement therapy (with a medication compliance component) delivered from trained counselors. Although more subjects in the active medication groups terminated the study early secondary to adverse events, the rates did not differ significantly from that of placebo. The 20-mg/d group experienced more insomnia, dizziness, and confusion, while the 5-mg group also had more dizziness and the 40-mg group had more nausea than the placebo group. Most of these symptoms were mild and improved over time. Although all subjects had a reduction in heavy drinking days, craving, gamma-glutamyl transferase, and carbohydrate-deficient transferrin concentrations over the course of the study, there was no difference between the active medication and placebo groups on these measures. The tim...Continue Reading

References

Nov 1, 1992·Archives of General Psychiatry·J R VolpicelliC P O'Brien
Nov 1, 1992·Archives of General Psychiatry·S S O'MalleyB Rounsaville
Nov 1, 1990·Pharmacology, Biochemistry, and Behavior·D L DeHaven-HudkinsL R Steranka
Jun 1, 1982·Journal of Abnormal Psychology·H A Skinner, B A Allen
Jan 1, 1981·Pharmacology, Biochemistry, and Behavior·H L AltshulerT S Shippenberg
Oct 1, 1994·Alcoholism, Clinical and Experimental Research·B J MasonE Mantero-Atienza
Oct 1, 1993·Journal of Medicinal Chemistry·C H MitchA E Takemori
Oct 1, 1996·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·B J BergJ R Volpicelli
Mar 9, 1999·Alcoholism, Clinical and Experimental Research·D DavidsonR Swift
Aug 6, 1999·Archives of General Psychiatry·B J MasonR B Cutler
Oct 8, 1999·Alcoholism, Clinical and Experimental Research·J S RobertsD H Moak
Jan 19, 2000·Pharmacology, Biochemistry, and Behavior·L D MiddaughE R Cuison
Mar 25, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·H R KranzlerJ Van Kirk
Nov 30, 2000·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·J ChickB Ritson
Oct 5, 2001·Alcoholism, Clinical and Experimental Research·H R Kranzler, J Van Kirk
Nov 13, 2001·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·C Streeton, G Whelan
Dec 14, 2001·The New England Journal of Medicine·J H KrystalUNKNOWN Veterans Affairs Naltrexone Cooperative Study 425 Group
Sep 13, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Roberto CiccocioppoFriedbert Weiss
Nov 28, 2002·Journal of Clinical Psychopharmacology·Markus GastparRobert Croop
Mar 26, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David J DrobesKonstantin Voronin
Feb 20, 2004·The American Journal on Addictions·Raymond F Anton, Robert M Swift

❮ Previous
Next ❯

Citations

Jul 25, 2013·CNS Drugs·Mark J Niciu, Albert J Arias
May 3, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Brendan M Walker, George F Koob
Jul 27, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Francesca M FilbeyKent E Hutchison
Nov 5, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Fabio CaputoMauro Bernardi
Nov 18, 2006·Expert Opinion on Pharmacotherapy·Michael Soyka, Susanne Roesner
Jun 22, 2010·Expert Opinion on Emerging Drugs·Michael Soyka, Susanne Rösner
Jun 10, 2011·Expert Opinion on Investigational Drugs·Thomas HillemacherHelge Frieling
Jun 7, 2005·Expert Opinion on Emerging Drugs·Raye Z LittenMark Egli
Sep 28, 2010·Expert Opinion on Investigational Drugs·Michael Soyka, Susanne Rösner
Feb 15, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael SoykaUNKNOWN WFSBP Task Force on Treatment Guidelines for Substance Use Disorders
Apr 2, 2013·Biological Psychiatry·Robert M Swift
Mar 2, 2016·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Raye Z LittenJoanne B Fertig
Aug 8, 2015·Human Psychopharmacology·Borwin Bandelow, Dirk Wedekind
Aug 10, 2005·Alcoholism, Clinical and Experimental Research·C AllingR A Harris
Jan 18, 2007·Fundamental & Clinical Pharmacology·Sophie Tambour, Etienne Quertemont
Jun 10, 2008·Alcoholism, Clinical and Experimental Research·Albert J AriasHenry R Kranzler
Nov 19, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Michael Soyka, Jochen Mutschler
Mar 30, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Julia M A SinclairDavid S Baldwin
Jul 26, 2005·Peptides·Richard J Bodnar, Gad E Klein
May 20, 2015·British Journal of Pharmacology·Florence NobleNicolas Marie
Jan 25, 2014·Expert Opinion on Pharmacotherapy·Christian A MüllerAndreas Heinz
May 20, 2015·Pharmacology & Therapeutics·A ThompsonM Pirmohamed
Apr 9, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Antoni GualUNKNOWN ESENSE 2 Study Group
Jul 3, 2013·Current Opinion in Neurobiology·Johan Franck, Nitya Jayaram-Lindström
Nov 20, 2013·The International Journal of Neuropsychopharmacology·Michael Soyka
Aug 4, 2016·Neurotoxicity Research·Patrycja KleczkowskaMagdalena Bujalska-Zadrozny
Aug 19, 2016·BMC Medicine·Florian NaudetBruno Laviolle
Jan 27, 2016·Expert Opinion on Pharmacotherapy·Michael Soyka
May 26, 2012·Journal of Psychopharmacology·A R Lingford-HughesUNKNOWN British Association for Psychopharmacology, Expert Reviewers Group
Jul 5, 2013·Journal of Psychopharmacology·Jan van Amsterdam, Wim van den Brink
Dec 23, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael SoykaUNKNOWN WFSBP Task Force on Treatment Guidelines for Substance Use Disorders
Feb 22, 2017·Alimentary Pharmacology & Therapeutics·E T Goh, M Y Morgan
Jul 1, 2017·Expert Opinion on Pharmacotherapy·Michael Soyka, Christian A Müller
Nov 18, 2006·Journal of Clinical Psychopharmacology·Helen M PettinatiCharles A Dackis
Jun 16, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kimmo IngmanHarry Scheinin
Jul 1, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gavin BartMary Jeanne Kreek
Oct 31, 2018·The American Journal of Drug and Alcohol Abuse·Lara A RayKaren Miotto

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.